Keyword: Pharmaceutical

151 results found
Collaboration fundamental when managing, altering private drug plans

As the landscape of Canadian drug plan management continues to evolve, several programs are being implemented by insurers and pharmacy benefits managers to help plan sponsors manage costs. Speaking on a panel at Benefits Canada’s 2019 Face to Face Drug Plan Management Forum on Dec. 3 in Toronto, Ned Pojskic, leader of pharmacy and health provider […]

A look at the legal risk for benefits plan sponsors

With Canada’s population ageing and research and development looking to produce medications that are beneficial for this evolving demographic, drugs are becoming more expensive, according to Mitch Frazer, partner and chair of the pensions and employment practice at Torys LLP.  In fact, among all the countries in the Organisation for Economic Co-operation and Development, Canada has the third […]

CN Rail workers continue strike over drug benefits, safety concerns

Roughly 3,200 Canadian National Railway Co. workers are on strike with outstanding issues including time-off provisions and lifetime caps on certain benefits. The strike, which began at midnight on Nov. 19, has seen conductors, train personnel and yard workers represented by the Teamsters Canada Rail Conference pushing for further bargaining progress on these issues and others, including safety and fatigue. […]

  • By: Staff
  • November 21, 2019 November 12, 2020
  • 09:23
Brand discount cards increase costs to private insurers by 46%: study

As the popularity of brand discount cards grows among Canadians, how much are people actually saving? And what’s the cost to insurers? In a study published in the Canadian Medical Association Journal, researchers waded through 2.82 million prescriptions for 89 different medications for which patients used brand discount cards. It found patients saved seven per cent, or $3.49 […]

  • By: Staff
  • November 18, 2019 November 11, 2020
  • 10:31
Institutional investors urging Congress to vote down CUSMA, citing effect on drug prices

A group of institutional investors representing more than US$500 billion is calling on the U.S. Congress to vote down the Canada-United States-Mexico trade agreement to prevent extended monopoly rights for pharmaceutical companies in all three countries. The Interfaith Center on Corporate Responsibility, which represents more than 300 religious institutional investors, pension funds, foundations, asset managers […]

Prescription drug costs for Canadian public plans hit $11.4 billion in 2017/18: report

Prescription drug costs for public drug plans covering most of Canada increased 7.4 per cent in 2017/18 to reach $11.4 billion, according to a new report by the Patented Medicine Prices Review Board. It’s a significant increase compared to the more modest 1.9 per cent growth in prescription drug costs from 2016/17. The board looked at data […]

  • By: Staff
  • September 12, 2019 November 12, 2020
  • 09:00
Pharma companies launching challenge to PMPRB changes

Five major pharmaceutical companies have filed a constitutional challenge to the federal government’s incoming changes to the Patented Medicine Prices Review Board. The complaint was filed in Quebec Superior Court by the Canadian subsidiaries of Merck & Co., Janssen Inc., Bayer, Boehringer Ingelheim Ltd. and Servier Inc. In statements provided to Benefits Canada, the companies […]

Caisse investing in Mexican pharmaceutical company

The Caisse de dépôt et placement du Québec is investing US$500 million in Laboratorios Sanfer, an independent Mexican pharmaceutical company. The company, which currently maintains a presence in 25 countries, has been focusing on growth through acquisitions for the past two decades, according to a press release. The investment from the Caisse will enable further […]

  • By: Staff
  • August 19, 2019 November 11, 2020
  • 15:00
Could Quebec’s public drug plan work for national pharmacare?

Quebec’s universal pharmacare program offers better drug coverage and quicker approval for new drugs coming to market than the rest of Canada, according to a new study by the Fraser Institute. Looking at drugs approved by Health Canada between 2008 and 2017, the report found Quebec went on to cover 33.4 per cent of them, […]

Sanofi survey finds plan sponsors, members misunderstand private drug plans

Plan sponsors and plan members are unaware of the key differences between private and public drug plans, according to the 2019 Sanofi Canada health-care survey. Both employer and employee respondents said they believe private and public prescription drug plans cover close to the same amount of medications. Plan members estimated about 6,600 drugs are covered under private […]

  • By: Staff
  • June 18, 2019 November 12, 2020
  • 09:00